Your browser doesn't support javascript.
loading
Cost-Effectiveness of Saxagliptin Compared To Glp-1 Analogues As An Add-On To Insulin in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
Charokopou, M; Vioix, H; Verheggen, B; Eddowes, L A; Griffiths, M; Gabriel, Z; Tolley, K; Sibartie, M.
Afiliação
  • Charokopou M; Pharmerit International, Rotterdam, The Netherlands.
  • Vioix H; AstraZeneca UK Ltd., Luton, UK.
  • Verheggen B; Pharmerit International, Rotterdam, The Netherlands.
  • Eddowes LA; Costello Medical Consulting Ltd., Cambridge, UK.
  • Griffiths M; Costello Medical Consulting, Cambridge, UK.
  • Gabriel Z; AstraZeneca UK Ltd., Luton, UK.
  • Tolley K; Tolley Health Economics Ltd., Buxton, Derbyshire, UK.
  • Sibartie M; AstraZeneca UK Ltd., Luton, UK.
Value Health ; 17(7): A347, 2014 Nov.
Article em En | MEDLINE | ID: mdl-27200661
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Evaluation_studies / Health_economic_evaluation Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Evaluation_studies / Health_economic_evaluation Idioma: En Ano de publicação: 2014 Tipo de documento: Article